Device Trial Radar · NCT03303612
Clinical Monitoring Strategy Versus Electrophysiology-guided Algorithmic Approach With a New LBBB After TAVI
Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
250
Planned (sponsor's estimate)
Start
Oct 15, 2017
Primary completion
Dec 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- Montreal Heart InstituteAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 6, 2017
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary hypothesis of the proposed study is that an electrophysiology-based algorithmic approach is superior to standard clinical follow-up with 30-day monitoring in reducing the combined endpoint of syncope, hospitalization, and death in patients in patients with new of left bundle branch block following transcatheter aortic valve implantation (TAVI).
Conditions
- Left Bundle-Branch Block
- Aortic Valve Stenosis
Interventions
Pacemaker implantDevice
Patient will be in the electrophysiology laboratory. The doctor will freeze the groin area and a medication may be given to help the patient relax. A catheter will be inserted into the groin up to the heart and the heart's electrical system will be recorded.
Transcutaneous cardiac monitorDevice
Transcutaneous cardiac patches will allow continuous electrocardiographic monitoring for a 30-day period. For the first randomized patients at the Montreal Heart Institute, Icentia was used and then was changed to a m-Health® device which allows continuous cardiac monitoring. The PocketECG from m-Health® is attached to 3 electrodes on the chest and contains a SIM card that transmits to a server located in Burlington, Ontario .The COME-TAVI coordinating center and the associated site will be informed rapidly of any events that occur . These events include: Ventricular fibrillation; Sustained ventricular tachycardia Any RR interval \>5 sec; Third-degree AV block or Mobitz 2 AV block;
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of patients with cardiovascular hospitalization, and/or syncope, and/or death after TAVI.Time frame: 12 months
Locations
10 sites in 2 countries. Site status is shown where the registry gives one.
Mazankowski Alberta Heart Institute
Edmonton, Alberta, Canada · Recruiting
New Brunswick Heart Center
Saint John, New Brunswick, Canada · Not yet recruiting
QEII Health Sciences Center
Halifax, Nova Scotia, Canada · Recruiting
7 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.